Your browser doesn't support javascript.
loading
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Genge, Angela; Pattee, Gary L; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Bidani, Sachin; Hirai, Manabu; Sakata, Takeshi; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E.
  • Genge A; Clinical Research and ALS Clinic, Montreal Neurological Institute and Hospital, Montreal, Canada.
  • Pattee GL; Neurological Sciences Department, University of Nebraska Medical Center, Lincoln, Nebraska, USA.
  • Sobue G; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Aoki M; Department of Neurology, Aichi Medical University, Nagakute, Japan.
  • Yoshino H; Department of Neurology, Tohoku University School of Medicine, Sendai, Japan.
  • Couratier P; Department of Neurology, Yoshino Neurology Clinic, Chiba, Japan.
  • Lunetta C; Department of Neurology, University Hospital of Limoges, Limoges, France.
  • Petri S; Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Unit of Milano, Milan, Italy.
  • Selness D; NEMO Clinical Center, Fondazione Serena Onlus, Milan, Italy.
  • Bidani S; Clinic for Neurology, Hannover Medical School, Hannover, Germany.
  • Hirai M; Clinical and Technical Operations, Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, New Jersey, USA.
  • Sakata T; Clinical Development, Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, New Jersey, USA.
  • Salah A; Clinical Research & Development, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Apple S; Global Products Management Department, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Wamil A; Medical Affairs, Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.
  • Kalin A; Medical Affairs, Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.
  • Jackson CE; Neurology, Medical Science, Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, New Jersey, USA.
Muscle Nerve ; 67(2): 124-129, 2023 02.
Article en En | MEDLINE | ID: mdl-36504406
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Edaravona / Esclerosis Amiotrófica Lateral Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Edaravona / Esclerosis Amiotrófica Lateral Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article